Galera Therapeutics, Inc.

Galera Therapeutics, Inc. could be a weak company given it's low Piotroski F-score. The momentum for this stock is not very good. Galera Therapeutics, Inc. is not a good value stock. Galera Therapeutics, Inc. is not very popular among insiders. Galera Therapeutics, Inc. is a mediocre stock to choose.

News

Galera Announces Board Approval of Complete Liquidation and Dissolution

Globe Newswire Company reports second quarter 2024 financial resultsMALVERN, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company...\n more…

Galera Therapeutics continues to explore options, again warns of potential shutdown

Bizjournals.com - Health Care News Galera's options include a merger, asset sales, divestiture and licensing arrangements.\n more…

GRTX Stock Earnings: Galera Therapeutics Reported Results for Q1 2024

InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nGalera Therapeutics just reported results for the first quarter of 2024.\nThe post GRTX Stock Earnings: Galera Therapeutics Reported...\n more…

Galera Therapeutics reports Q1 EPS (8c) vs (50c) last year

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates

Globe Newswire Company's evaluation of potential strategic alternatives progresses with goal to maximize stockholder valueMALVERN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a...\n more…

Galera Therapeutics Enacts Plan to Deter Hostile Takeovers

TipRanks Financial Blog Galera Therapeutics (GRTX) has issued an update. Galera Therapeutics, Inc. has implemented a stockholder rights plan, issuing one Right per common share, allowing s...\n more…